Top

Neurological Sciences

Published in:

01-07-2021 | Deep Brain Stimulation | Brief Communication

Device-aided therapies for advanced Parkinson disease: insights from an international survey

Authors: Luca Marsili, Matteo Bologna, Janis M. Miyasaki, Carlo Colosimo

Published in: Neurological Sciences | Issue 7/2021

Abstract

Purpose

In the advanced stage of Parkinson disease (PD), therapeutic interventions include device-aided therapies such as continuous subcutaneous apomorphine infusion (CSAI), levodopa-carbidopa intestinal gel (LCIG) infusion, and deep brain stimulation (DBS). Recent evidence has underlined the general lack of randomized, blinded, head-to-head studies on device-aided therapies for advanced PD.

Methods

To better clarify the real-world attitude of clinicians on this matter, we conducted an international survey of forty-four experienced movement disorder specialists regarding the management of device-aided therapies in advanced PD.

Results

Our international survey showed a general agreement that nowadays, motor complications are less common compared to the past (59% agreement), that guidelines to identify candidates for device-aided therapies are currently lacking (57% agreement), and that device-aided therapies will have increased demand in the future (75% agreement).

Conclusions

We conclude that guidelines to assist clinicians and patients to choose device-aided therapies are required.

Coelho M, Ferreira JJ (2012) Late-stage Parkinson disease. Nat Rev Neurol 8C:435–442. https://doi.org/10.1038/nrneurol.2012.126CrossRef

Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH, Bezard E, Picconi B, Calabresi P, Lang AE (2018) Levodopa-induced dyskinesia in Parkinson disease: current and evolving concepts. Ann Neurol 84:797–811. https://doi.org/10.1002/ana.25364CrossRefPubMed

Colosimo C, Marsili L (2015) Treatment of Parkinson’s disease. In: Colosimo C, Gil-Nagel A, Gilhus NE, Rapoport A, Williams O (eds) Handbook of neurological therapy. Oxford University Press, New York, pp 293–306

Marsili L, Vizcarra JA, Sturchio A, Dwivedi AK, Keeling EG, Patel D, Mishra M, Farooqi A, Merola A, Fasano A, Mata IF, Kauffman MA, Espay AJ (2020) When does postural instability appear in monogenic parkinsonisms? An individual-patient meta-analysis. J Neurol. https://doi.org/10.1007/s00415-020-09892-3

Fabbri M, Rosa MM, Ferreira JJ (2018) Adjunctive therapies in Parkinson’s disease: how to choose the best treatment strategy approach. Drugs Aging 35:1041–1054. https://doi.org/10.1007/s40266-018-0599-2CrossRefPubMed

Marsili L, Bologna M, Miyasaki JM, Colosimo C (2020) Parkinson’s disease advanced therapies - a systematic review: more unanswered questions than guidance. Parkinsonism Relat Disord S1353-8020(20):30843–30849. https://doi.org/10.1016/j.parkreldis.2020.10.042CrossRef

Fabbri M, Pongmala C, Artusi CA, Imbalzano G, Romagnolo A, Lopiano L, Zibetti M (2020) Video analysis of long-term effects of levodopa-carbidopa intestinal gel on gait and posture in advanced Parkinson’s disease. Neurol Sci 41:1927–1930. https://doi.org/10.1007/s10072-020-04319-3CrossRefPubMed

Pickut BA, van der Linden C, Dethy S, Van De Maele H, Zegers de Beyl D (2014) Intestinal levodopa infusion: the Belgian experience. Neurol Sci 35:861–866. https://doi.org/10.1007/s10072-013-1612-5CrossRefPubMed

Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, Onuk K, Odin PLA (2018) Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Curr Med Res Opin 34:2063–2073. https://doi.org/10.1080/03007995.2018.1502165CrossRefPubMed

10.

Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A et al (2004) Parkinson Study Group Levodopa and the progression of Parkinson’s disease. N Engl J Med 351:2498–2508. https://doi.org/10.1056/NEJMoa033447CrossRefPubMed

11.

de Bie RMA, Clarke CE, Espay AJ, Fox SH, Lang AE (2020) Initiation of pharmacological therapy in Parkinson’s disease: when, why, and how. Lancet Neurol 19:452–461. https://doi.org/10.1016/S1474-4422(20)30036-3CrossRefPubMed

Title: Device-aided therapies for advanced Parkinson disease: insights from an international survey
Authors: Luca Marsili
Matteo Bologna
Janis M. Miyasaki
Carlo Colosimo
Publication date: 01-07-2021
Publisher: Springer International Publishing
Keywords: Deep Brain Stimulation
Parkinson's Disease
Movement Disorder
Carbidopa
Levodopa
Apomorphine
Published in: Neurological Sciences / Issue 7/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-021-05106-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Device-aided therapies for advanced Parkinson disease: insights from an international survey

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2021

Neuroimaging in idiopathic adult-onset focal dystonia

Does anodal trans-cranial direct current stimulation of the damaged primary motor cortex affects wrist flexor muscle spasticity and also activity of the wrist flexor and extensor muscles in patients with stroke?: a Randomized Clinical Trial

The autonomic nervous system in pathography

Acute psychotic onset in LGI1-related limbic encephalitis

Long-segment diffuse cervical spinal cord involvement as the first episode of neuro-Behçet’s disease: a case report

Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results